These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3287 related articles for article (PubMed ID: 28539557)

  • 21. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
    Jin C; Yu D; Essand M
    Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
    Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
    Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
    Nielsen AY; Ormhøj M; Traynor S; Gjerstorff MF
    Cancer Immunol Immunother; 2020 Nov; 69(11):2169-2178. PubMed ID: 32648166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
    Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
    Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.
    Xu J; Tian K; Zhang H; Li L; Liu H; Liu J; Zhang Q; Zheng J
    Expert Rev Anticancer Ther; 2017 Dec; 17(12):1099-1106. PubMed ID: 29048935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric Antigen Receptors for the Tumour Microenvironment.
    Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
    Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
    Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
    J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Adoptive cell therapy for solid tumors].
    Sakamoto K; Yagyu S
    Rinsho Ketsueki; 2024; 65(7):652-661. PubMed ID: 39098016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating CAR-T Cell Therapy in a Hypoxic 3D Tumor Model.
    Ando Y; Siegler EL; Ta HP; Cinay GE; Zhou H; Gorrell KA; Au H; Jarvis BM; Wang P; Shen K
    Adv Healthc Mater; 2019 Mar; 8(5):e1900001. PubMed ID: 30734529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving homing in T cell therapy.
    Vignali D; Kallikourdis M
    Cytokine Growth Factor Rev; 2017 Aug; 36():107-116. PubMed ID: 28690108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
    Abken H
    Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 165.